VA Houston Healthcare System Selects ViewRay to Expand Advanced Radiation Therapy Services
ViewRay, Inc. (Nasdaq: VRAY) announced that the VA Houston Healthcare System has selected the MRIdian MRI-guided radiation therapy system, becoming the first hospital in Texas and third VA hospital to do so. This technology will enhance cancer treatment options for veterans with various cancers, including pancreas and prostate. The MRIdian system offers real-time MRI visualization and adaptive therapy, improving treatment precision while minimizing exposure to healthy tissue. With nearly 25,000 patients treated and 53 systems installed worldwide, ViewRay continues to innovate in advanced radiation therapy.
- Expanded treatment options for veterans in Texas with the introduction of MRIdian.
- Improved cancer treatment precision through real-time MRI visualization and adaptive therapy.
- Strong market presence with nearly 25,000 patients treated using MRIdian technology.
- None.
This is the First Hospital in Texas and the Third VA Hospital to Offer MRIdian® MRI-guided Radiation Therapy Cancer Treatment.
DENVER, Aug. 23, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the VA Houston Healthcare System has selected a MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Michael E. DeBakey VA Medical Center. The MRIdian system will enable the VA Houston Cancer Program to offer advanced MRI-guided radiation therapy technology to Veterans throughout the region who are seeking personalized treatment for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.
VA Houston Healthcare System provides state-of-the-art healthcare services to Veterans at 12 locations of care in southeast Texas and is one of the leading healthcare systems serving Veterans in the South-Central VA Health Care Network. They are an innovative care center within the Veterans Integrated Service Network 16 (VISN 16), which includes medical centers and clinics in Mississippi, Louisiana, Arkansas, Oklahoma, southeast Texas, and northwest Florida. The Michael E. DeBakey VA Medical Center joins the Lieutenant Colonel Charles S. Kettles VA Medical Center (VA Ann Arbor Healthcare System) and the Louis Stokes Cleveland VA Medical Center (VA Northeast Ohio Healthcare System) as the third Veteran's Affairs facility to invest in MRIdian SMART (stereotactic MR-guided adaptive radiotherapy), which combines the benefits of real-time MRI visualization, on-table adaptive therapy, and automatic beam control, to allow clinicians to deliver precise radiation therapy treatment.
"ViewRay is excited to see another VA Healthcare system join the MRIdian community. This is a testament to their dedication and commitment to bringing the most advanced radiation therapy to our Veterans," said Paul Ziegler, Chief Commercial Officer at ViewRay. "Thousands of patients treated on MRIdian prove compelling and consistent clinical outcomes in both tough to treat and more common cancers. Patients demand short-course non-invasive therapy with fewer side effects and the VA is clearly committed to delivering that to every patient they serve."
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions, without relying on implanted markers. By providing real-time continuous tracking of the target and organs-at-risk, MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins. This allows for delivery of the prescribed dose to the target, while sparing surrounding healthy tissue and critical structures, which results in minimizing toxicities typically associated with conventional radiation therapy
To date, nearly 25,000 patients have been treated with MRIdian. Currently, 53 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/
The opinions and clinical experiences discussed herein are specific to the featured physicians and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in this press release are not indicative of typical or future results.
The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary, or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration. Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, ViewRay's financial guidance for the full year 2022, anticipated future orders, anticipated future operating and financial performance, treatment results, therapy adoption, innovation, and the performance of the MRIdian systems. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize the MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, the timing of delivery of ViewRay's products, the timing, length, and severity of the COVID-19 pandemic, including its impacts across our businesses on demand, our operations and global supply chains, disruptions in the supply or changes in costs of raw materials, labor, product components or transportation services as a result of inflation, the results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates, and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and its Quarterly Reports on Form 10-Q, as updated periodically with the Company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
View original content:https://www.prnewswire.com/news-releases/va-houston-healthcare-system-selects-viewray-to-expand-advanced-radiation-therapy-services-301610428.html
SOURCE ViewRay, Inc.
FAQ
What is the significance of ViewRay's MRIdian system in cancer treatment for veterans?
Which VA hospitals have adopted the MRIdian technology?
How many patients have been treated with the MRIdian system to date?
What types of cancers can be treated with the MRIdian MRI-guided radiation therapy?
What benefits does the MRIdian system provide over conventional radiation therapy?
